Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Z Best Place to Talk Stocks -- Ignore unavailable to you. Want to Upgrade?

To: Larry S. who wrote (36065)	12/18/2001 12:35:26 PM
From: Mkilloran	Read Replies (1) \| Respond to of 53068

Larry S..I'm looking for AMRN to recover quickly to it's 100 day M/A and move onto new highs from there. Plenty of support at the 200 day M/A level. ---------- The Chart Room has received several e-mails about previously featured pharmaceutical stock pick Amarin , which was recommended by Dennis Slothower, the editor ofOn The Money. Slothower recommended the stock at $24.50 on Nov. 1 (see "Amarin: A Remedy For Ailing Portfolios"). It climbed to nearly $29, but has since retreated to $17. For those who didn't follow his advice and put a stop loss in at $20, hang in there. Slothower is still a buyer. "I think the decline is mostly from sector fund managers shifting their holdings." He sees considerable support at the $15 to $16 level for Amarin since August, and thinks the stock has bottomed. "I have it valued at $41," Todd says. "I think people will move back into more defensive stocks like health care as the market corrects and I still expect it to double in six months." Send comments and questions toinvestingnewsletters@forbes.net.